news
New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment responseNew evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response
biomarker, biomarkers, clopidogrel, diabetes, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR, type 2 diabetes mellitus
New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response
We want to draw your attention to the latest publication of the King's College London, in Cardiovascular Diabetology. The research team provides new evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response in type-2 diabetics with cardiovascular disease. "Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels." Parker WAE, Schulte C, Bawari T, et al. Cardiovasc Diabetol. 2020 Jan 7;19(1):3. doi: 10.1186/s12933-019-0981-3. click here to [...]
meet TAmiRNA 2020
2020 TAmiRNA showcases at several conferences - take advantage, meet the TAmiRNA experts and discuss our latest developments and your needs! 2nd Longevity Therapeutics conference, 28-30 January 2020, San Francisco, California, USA SOT 59th Annual Meeting and ToxExpo, 15-19 March 2020, Anaheim, California, USA - cancelled Osteologie 2020, 5-6 September 2020, virtual meeting 47th annual meeting of the European Calcified Tissue Society, 22-24 [...]
MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.
biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, osteomiR, osteoporosis, Personalized medicine
MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.
We want to draw your attention to the latest publication of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in AUVA Research Center, in cooperation with TAmiRNA GmbH, in Bone. "MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis." Kocijan R, Weigl M, Skalicky S, et al. Bone 2019 Volume 131, February [...]
Serum microRNA as novel biomarkers for osteoporotic vertebral fractures.
We want to draw your attention to the latest publication of the Department of Oncology and Metabolism, University of Sheffield, United Kingdom, in cooperation with TAmiRNA GmbH, in Bone. "Serum microRNA as novel biomarkers for osteoporotic vertebral fractures." Zarecki P, Hackl M, Grillari J, et al. Bone 2019 Oct 24:115105. doi: 10.1016/j.bone.2019.115105. Specific circulating miRNAs reflect the presence of osteoporotic vertebral fractures in [...]
Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissuesCombining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues
biomarker, biomarkers, drug development, drug discovery, LMD, microRNAs, Personalized medicine, safety, Vivomicx
Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues
We want to draw your attention to the latest publication with our partner Vivomicx. Together we have developed a combination of laser microdissection (LMD) and high quality qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets [...]
meet TAmiRNA 2019
2019 TAmiRNA showcases at several conferences 63rd Annual Meeting of the Society of Thrombosis and Haemostasis Research, 27 February-2 March 2019, Berlin, Germany 9th international Gene Quantification Event, 18-22 March, Freising-Weihenstephan, Germany ECTS (European Calcified Tissue Society) 2019, 11-14 May 2019, Budapest, Hungary The 9th International Conference on Children’s Bone Health, 22-25 June 2019, Salzburg, Austria British Orthopaedic Society, 4-6 September 2019, Cardiff, UK ASBMR 2019 [...]
TAmiRNA GmbH is part of the EU-funded Innovative Training Network FIDELIO
Diabetes mellitus is a widespread metabolic disease, with negative/adverse effects on many organ systems. Diabetes also significantly affects bone health. An increased risk of bone fractures and impaired fracture healing has been observed in patients, but the mechanisms are not fully understood. In order to investigate the links between diabetes and the bone system, the EU project "FIDELIO" will run for four years [...]
University Medical Center Groningen (UMCG) , TAmiRNA GmbH & Vivomicx BV announce their collaboration to unmask the molecular signature of sepsis induced multi organ failure.University Medical Center Groningen (UMCG) , TAmiRNA GmbH & Vivomicx BV announce their collaboration to unmask the molecular signature of sepsis induced multi organ failure.
University Medical Center Groningen (UMCG) , TAmiRNA GmbH & Vivomicx BV announce their collaboration to unmask the molecular signature of sepsis induced multi organ failure.
UMCG, TAmiRNA, and Vivomicx today announced their collaboration to unmask the molecular signature of sepsis induced multi organ failure and shed light on diagnosis and therapeutic options. Sepsis is the body’s response to infection. Sepsis kills and disables millions of patients worldwide. The role of the microvasculature in all organs has been identified as central, yet understudied in the pathophysiology leading to Multi [...]
TAmiRNA and advanceCOR receive Eurostars project “thrombomiR”
TAmiRNA and advanceCOR, a drug developing biotechnology company which focuses on personalized medicine in cardiovascular diseases, receive Eurostars project entitled: ”A novel microRNA-based platelet function biomarker for personalized anti-thrombotic treatment”. The aim of the Eurostars project is to validate the use of the thrombomiR™ kit for management of anti-thrombotic therapies. The thrombomiR™ kit is a minimally invasive blood test that can determine changes [...]
TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”
Early and reliable detection and monitoring of adverse events is essential for improving of patient safety, reducing late attrition of drug candidates, and enhancing understanding of toxic mechanisms. The Translational Safety Biomarker Pipeline (TransBioLine) project will focus on development of biomarkers of injury for liver, kidney, pancreas, vasculature, central nervous system (CNS) and the development of non-invasive microRNA biomarkers using liquid biopsies. The [...]